Interplay Between Oxytocin and Cortisol During Stress in Borderline Personality Disorder (OXT-CORT-BPD)

May 13, 2025 updated by: Tatiana Aboulafia Brakha, University of Geneva, Switzerland

Feasibility and Preliminary Data on the Interplay Between Oxytocin and Cortisol During Stress in Borderline Personality Disorder

This study aims to determine the feasibility and preliminary data on the interaction between oxytocin and cortisol during stress in borderline personnality disorder.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

The investigators will recruit 50 female patients with borderline personnality disorder and 50 controls with no psychiatric diagnosis, aged between 18 and 25 years old.

salivary cortisol daily curve ( 6 measures during the day) will be measured in participant's naturalistic environnement, together with salivary oxytocin. In addition, salivary oxytocin and cortisol will be measured during a psychosocial stress task and recovery.

Study Type

Observational

Enrollment (Actual)

100

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Switzerland
      • Geneva, Switzerland, 1202
        • Young Adult Psychiatric Unit

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 25 years (Adult)

Accepts Healthy Volunteers

Yes

Sampling Method

Non-Probability Sample

Study Population

Participants with and without borderline personality disorder

Description

Inclusion Criteria:

  • Borderline personality disorder-DSM V

Exclusion Criteria:

  • Schizophrenia

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Borderline personality disorder
female patients between 18 and 25 years old meeting DSM V criteria for borderline personality disorder
Other: stress test
TSST- psychosocial stress test
Control
female participants between 18 and 25 years old, with no psychiatric history, not meeting criteria for borderline personality disorder
Other: stress test
TSST- psychosocial stress test

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Salivary cortisol
Time Frame: Baseline
salivary cortisol measured with salivettes (swabs)
Baseline
Salivary cortisol
Time Frame: Change in one day (circadian cortisol with 6 measures within one day
salivary cortisol measured with salivettes (swabs)
Change in one day (circadian cortisol with 6 measures within one day
Salivary cortisol
Time Frame: Change during experimental task (up to 2 hours)
salivary cortisol measured with salivettes (swabs)
Change during experimental task (up to 2 hours)
Salivary oxytocin
Time Frame: Baseline
salivary oxytocin measured with salivettes (swabs)
Baseline
Salivary oxytocin
Time Frame: Two measures within one day
salivary oxytocin measured with salivettes (swabs)
Two measures within one day
Salivary oxytocin
Time Frame: Change during experimental task (up to 2 hours)
salivary oxytocin measured with salivettes (swabs)
Change during experimental task (up to 2 hours)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University of Geneva, Switzerland

Investigators

  • Principal Investigator: Tatiana Aboulafia Brakha, PhD, Geneva Univeristy hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 1, 2022

Primary Completion (Actual)

March 30, 2025

Study Completion (Actual)

April 30, 2025

Study Registration Dates

First Submitted

March 5, 2022

First Submitted That Met QC Criteria

April 26, 2022

First Posted (Actual)

May 3, 2022

Study Record Updates

Last Update Posted (Actual)

May 16, 2025

Last Update Submitted That Met QC Criteria

May 13, 2025

Last Verified

March 1, 2024

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 2002-00067

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Borderline Personality Disorder

Clinical Trials on stress test

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Burundi

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe